Cipla gets 1 inspectional observation from USFDA for Maha facility
Mumbai: Pharma giant Cipla has informed through a recent BSE filing that the Company has received 1 inspectional observation in Form 483 from the United States Food and Drug Administration (USFDA) at the conclusion of the inspection at Kurkumbh manufacturing facility.
The inspection was held from 29th April, 2024 to 8th May, 2024.
"A routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at manufacturing facility of the Company located in Kurkumbh, Maharashtra, India from 29th April, 2024 to 8th May, 2024," Cipla stated.
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
"The Company will work closely with the USFDA and is committed to address this observation comprehensively within stipulated time," Drug major added.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.